Endocrine Abstracts

Neuroendocrine tumors (NETs) constitute a rather heterogenous group of malignancies that are considered to be rare. However, resent data is indicating a significant increase in both incidence and prevalence over the last decades, with an overall incidence of 5/100 000/year and prevalence of 25/100 000/year.The treatment of NETs is based on the tumor biology (proliferation capacity and differentiation), tumor localisation and spread (TNM-staging). Surgery...

A unique feature of neuroendocrine tumors is that they express peptide hormone receptors. All five subtypes of somatostatin receptors are expressed in neuroendocrine tumors with dominance for receptor type 2 (SST2). Stimulation of SST2 can not only inhibit hormone release from the tumor, but also tumor cell growth. Both SST2 and 3 are involved in apoptosis of neuroendocrine tumor cells. SST’s in intratumoral blood vessels might implicate a role of anti-angiogenesis of som...

Background: NETs are a rare heterogeneous group of malignancies, often with a delayed diagnosis. Although diagnosis of NETs is increasing (due in part to greater awareness), little has been published on the NET patient experience. We present data on the EU NET patient perspective.Methods: In 2014, 1928 NET patients from >12 countries, including EU (n=763: Belgium, Bulgaria, France, Germany, Norway, UK, other EU countries (not specified by re...

Introduction: There is a substantial unmet clinical need for an accurate and effective blood biomarker for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Current monoanalyte biomarkers are ineffective. The NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. We therefore evaluated, under real-world conditions, the clinical utility of the NETest as a liquid biopsy in GEP-NETs.Aim(s): Independently ...

Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scor...

Background: Telotristat etiprate (TE), an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome (CS) by reducing serotonin production. TE was evaluated in TELESTAR, a phase 3 study; the primary endpoint showed significant reductions in bowel movement (BM) frequency for 2 TE dosages + standard of care (SOC) vs. SOC. TELESTAR patients had CS inadequately controlled on somatostatin analog therapy with ≥4 BMs per day. They were interviewed about base...